This study is testing a drug called atrasentan for people with IgA nephropathy (IgAN), a kidney disease. It's a phase 2 trial, which means researchers are checking how well the drug works and if it's safe. The study compares atrasentan to a placebo, a pill that looks like the drug but has no medicine in it. Participants will continue their regular kidney treatments and take an SGLT2 inhibitor (SGLT2i), a medicine that helps the kidneys.
About 52 people will be part of this study. They will receive atrasentan for one period and placebo for another, with a break in between. The study lasts for about 52 weeks (1 year).
- Participants must be 18 or older, have IgAN, and be on stable kidney medication.
- They cannot have other kidney diseases or recent history of cancer.
- Participants will have regular check-ups to monitor safety and effectiveness.
Those interested should discuss with their doctor to see if they fit the criteria and are comfortable with the study requirements, including regular visits and medication adherence.